FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Can Vet J / Pharmacokinetics and bioequivalence of 2 meloxicam oral dosa...
The Canadian veterinary journal = La revue veterinaire canadienne2015; 56(7); 730-736;

Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses.

Abstract: Meloxicam, a non-steroidal anti-inflammatory drug, is approved for use in horses in several countries, but an equine formulation is not available in North America. However, meloxicam is being used in an extra-label manner in horses in Canada. The purpose of this study, therefore, was to assess the bioequivalence of an approved oral meloxicam suspension (Metacam 15 mg/mL for horses; Boehringer Ingelheim Vetmedica GmBH, Ingelheim, Germany) from the European Union with human meloxicam tablets (Meloxicam 15 mg tablets; TEVA Canada, Toronto, Ontario) compounded with molasses to improve palatability and administration. The geometric mean ratios (GMR test/reference) and the 90% confidence intervals of the pivotal pharmacokinetic parameters (area under the curve and maximum concentration) were within the defined limits of 80% to 125% generally accepted for products to be considered bioequivalent. Therefore, use of human meloxicam tablets compounded with molasses would be expected to produce a similar clinical response in horses as the approved oral product from the European Union. Le méloxicam, un médicament anti-inflammatoire non stéroïdien, est approuvé pour utilisation chez les chevaux dans plusieurs pays, mais une formulation équine n’est pas disponible en Amérique du Nord. Cependant, le méloxicam est utilisé en dérogation des directives de l’étiquette chez les chevaux du Canada. Par conséquent, le but de la présente étude était d’évaluer la bioéquivalence d’une suspension orale approuvée de méloxicam (Metacam 15 mg/ml pour les chevaux; Boehringer Ingelheim Vetmedica GmBH, Ingelheim, Allemagne) de l’Union européenne avec celle des comprimés de méloxicam pour les humains (comprimés de 15 mg de méloxicam; TEVA Canada, Toronto, Ontario) préparés avec de la mélasse pour améliorer la sapidité et l’administration. Les ratios géométriques moyens (test RGM/référence) et les intervalles de confiance de 90 % des paramètres phamacocinétiques clés (secteur sous la courbe et concentration maximale) se situaient dans les limites définies de 80 % à 125 % généralement attendues pour des produits considérés comme bioéquivalents. Par conséquent, l’utilisation des comprimés de méloxicam pour humains préparés avec de la mélasse devrait produire une réponse clinique semblable chez les chevaux à celle du produit oral approuvé provenant de l’Union européenne.(Traduit par Isabelle Vallières).
Get Full Text
Publication Date: 2015-07-02 PubMed ID: 26130835PubMed Central: PMC4466825
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study has compared the effects of an approved European equine oral formulation of meloxicam, an anti-inflammatory drug, with a human version of the drug compounded with molasses, in horses. The study discovered that the human formula is just as effective as the equine formula, providing a valuable alternative for use in North America where the equine formulation is not available.

Objective and Need for the Research

  • The main intention of the research was to evaluate if the human version of meloxicam when combined with molasses can provide equivalent bioavailability as the approved equine variant of the drug from the European Union.
  • As the equine version of meloxicam – a non-steroidal anti-inflammatory drug – is not available in North America, there had been instances where veterinarians were using the human formula in an extra-label manner. This study aimed to understand and confirm the effectiveness and safety of such actions.

Process and Methodology

  • The researchers compared two versions of the drug – Metacam 15 mg/mL for horses from Boehringer Ingelheim Vetmedica and Meloxicam 15 mg tablets from TEVA Canada. The latter being a human dosage form and was compounded with molasses to improve palatability and facilitate administration in horses.
  • The bioequivalence was measured based on pivotal pharmacokinetic parameters that include ‘area under the curve’ and ‘maximum concentration’.

Findings

  • The geometric mean ratios (GMR test/reference) and the 90% confidence intervals calculated for these pharmacokinetic parameters fell within the average rule-of-thumb limits of 80% to 125%. This boundary range is typically followed when considering whether two products are bioequivalent.
  • Based on these findings, the researchers concluded that the human variant of meloxicam, when mixed with molasses, can be expected to induce a similar clinical response in horses as the approved equine oral formula from the European Union.

Relevance and conclusion

  • This research offers hope for veterinarians in North America in treating horses with a suitable alternative of an anti-inflammatory drug. The lack of a horse-specific formula of meloxicam in the region now has a potential solution with a compounded version of the human meloxicam tablet.

Cite This Article

APA
Vivancos M, Barker J, Engbers S, Fischer C, Frederick J, Friedt H, Rybicka JM, Stastny T, Banse H, Cribb AE. (2015). Pharmacokinetics and bioequivalence of 2 meloxicam oral dosage formulations in healthy adult horses. Can Vet J, 56(7), 730-736.

Publication

The Canadian veterinary journal = La revue veterinaire canadienne
ISSN: 0008-5286
NlmUniqueID: 0004653
Country: Canada
Language: English
Volume: 56
Issue: 7
Pages: 730-736

Researcher Affiliations

Vivancos, Melanie
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Barker, Jessica
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Engbers, Sarah
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Fischer, Carrie
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Frederick, Jami
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Friedt, Heather
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Rybicka, Joanna M
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Stastny, Tereza
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Banse, Heidi
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.
Cribb, Alastair E
  • Faculty of Veterinary Medicine, University of Calgary, 3280 Hospital Drive NW, Calgary, Alberta, Canada T2N 4Z6.

MeSH Terms

  • Administration, Oral
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacokinetics
  • Area Under Curve
  • Cross-Over Studies
  • Dosage Forms
  • Female
  • Half-Life
  • Horses / blood
  • Horses / metabolism
  • Male
  • Meloxicam
  • Therapeutic Equivalency
  • Thiazines / administration & dosage
  • Thiazines / chemistry
  • Thiazines / pharmacokinetics
  • Thiazoles / administration & dosage
  • Thiazoles / chemistry
  • Thiazoles / pharmacokinetics

References

This article includes 25 references
  1. Lees P. Pharmacology of drugs used to treat osteoarthritis in veterinary practice.. Inflammopharmacology 2003;11(4):385-99.
    pubmed: 15035792doi: 10.1163/156856003322699564google scholar: lookup
  2. Valverde A, Gunkel CI. Pain management in horses and farm animals.. J Vet Emerg Crit Care 2005;15:295–307.
  3. Soma LR, Uboh CE, Maylin GM. The use of phenylbutazone in the horse.. J Vet Pharmacol Ther 2012 Feb;35(1):1-12.
    pubmed: 21668837doi: 10.1111/j.1365-2885.2011.01299.xgoogle scholar: lookup
  4. Lees P, Higgins AJ. Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse.. Equine Vet J 1985 Mar;17(2):83-96.
    pubmed: 3987667doi: 10.1111/j.2042-3306.1985.tb02056.xgoogle scholar: lookup
  5. Meschter CL, Gilbert M, Krook L, Maylin G, Corradino R. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study.. Equine Vet J 1990 Jul;22(4):255-63.
    pubmed: 2209522doi: 10.1111/j.2042-3306.1990.tb04264.xgoogle scholar: lookup
  6. Read WK. Renal medullary crest necrosis associated with phenylbutazone therapy in horses.. Vet Pathol 1983 Nov;20(6):662-9.
    pubmed: 6649337doi: 10.1177/030098588302000602google scholar: lookup
  7. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance.. Inflamm Res 1995 Oct;44(10):423-33.
    pubmed: 8564518doi: 10.1007/bf01757699google scholar: lookup
  8. Noble S, Balfour JA. Meloxicam.. Drugs 1996 Mar;51(3):424-30; discussion 431-32.
    pubmed: 8882380doi: 10.2165/00003495-199651030-00007google scholar: lookup
  9. Beretta C, Garavaglia G, Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.. Pharmacol Res 2005 Oct;52(4):302-6.
    pubmed: 15939622doi: 10.1016/j.phrs.2005.04.004google scholar: lookup
  10. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats.. Am J Vet Res 2001 Nov;62(11):1755-60.
    pubmed: 11703020doi: 10.2460/ajvr.2001.62.1755google scholar: lookup
  11. Radi ZA, Khan NK. Effects of cyclooxygenase inhibition on the gastrointestinal tract.. Exp Toxicol Pathol 2006 Nov;58(2-3):163-73.
    pubmed: 16859903doi: 10.1016/j.etp.2006.06.004google scholar: lookup
  12. Little D, Brown SA, Campbell NB, Moeser AJ, Davis JL, Blikslager AT. Effects of the cyclooxygenase inhibitor meloxicam on recovery of ischemia-injured equine jejunum.. Am J Vet Res 2007 Jun;68(6):614-24.
    pubmed: 17542694doi: 10.2460/ajvr.68.6.614google scholar: lookup
  13. D'Arcy-Moskwa E, Noble GK, Weston LA, Boston R, Raidal SL. Effects of meloxicam and phenylbutazone on equine gastric mucosal permeability.. J Vet Intern Med 2012 Nov-Dec;26(6):1494-9.
    pubmed: 23083114doi: 10.1111/j.1939-1676.2012.01004.xgoogle scholar: lookup
  14. Vander Werf KA, Davis EG, Kukanich B. Pharmacokinetics and adverse effects of oral meloxicam tablets in healthy adult horses.. J Vet Pharmacol Ther 2013 Aug;36(4):376-81.
    pubmed: 23067209doi: 10.1111/jvp.12021google scholar: lookup
  15. Kreuder AJ, Coetzee JF, Wulf LW, Schleining JA, KuKanich B, Layman LL, Plummer PJ. Bioavailability and pharmacokinetics of oral meloxicam in llamas.. BMC Vet Res 2012 Jun 21;8:85.
    pmc: PMC3476427pubmed: 22720782doi: 10.1186/1746-6148-8-85google scholar: lookup
  16. Sinclair MD, Mealey KL, Matthews NS, Peck KE, Taylor TS, Bennett BS. Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys.. Am J Vet Res 2006 Jun;67(6):1082-5.
    pubmed: 16740106doi: 10.2460/ajvr.67.6.1082google scholar: lookup
  17. Lacasse C, Gamble KC, Boothe DM. Pharmacokinetics of a single dose of intravenous and oral meloxicam in red-tailed hawks (Buteo jamaicensis) and great horned owls (Bubo virginianus).. J Avian Med Surg 2013 Sep;27(3):204-10.
    pubmed: 24344511doi: 10.1647/2012-044google scholar: lookup
  18. Toutain PL, Reymond N, Laroute V, Garcia P, Popot MA, Bonnaire Y, Hirsch A, Narbe R. Pharmacokinetics of meloxicam in plasma and urine of horses.. Am J Vet Res 2004 Nov;65(11):1542-7.
    pubmed: 15566093doi: 10.2460/ajvr.2004.65.1542google scholar: lookup
  19. Toutain PL, Cester CC. Pharmacokinetic-pharmacodynamic relationships and dose response to meloxicam in horses with induced arthritis in the right carpal joint.. Am J Vet Res 2004 Nov;65(11):1533-41.
    pubmed: 15566092doi: 10.2460/ajvr.2004.65.1533google scholar: lookup
  20. de Grauw JC, van de Lest CH, Brama PA, Rambags BP, van Weeren PR. In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis.. Equine Vet J 2009 Sep;41(7):693-9.
    pubmed: 19927589doi: 10.2746/042516409x436286google scholar: lookup
  21. Noble G, Edwards S, Lievaart J, Pippia J, Boston R, Raidal SL. Pharmacokinetics and safety of single and multiple oral doses of meloxicam in adult horses.. J Vet Intern Med 2012 Sep-Oct;26(5):1192-201.
    pubmed: 22860573doi: 10.1111/j.1939-1676.2012.00976.xgoogle scholar: lookup
  22. Raidal SL, Edwards S, Pippia J, Boston R, Noble GK. Pharmacokinetics and safety of oral administration of meloxicam to foals.. J Vet Intern Med 2013 Mar-Apr;27(2):300-7.
    pubmed: 23425143doi: 10.1111/jvim.12045google scholar: lookup
  23. Health Canada. Policy on Manufacturing and Compounding Drug Products in Canada. [Last accessed May 20, 2015]. Available from: http://www.hc-sc.gc.ca/dhp-mps/compli-conform/gmp-bpf/docs/pol_0051-eng.php.
  24. Dasandi B, Shivaprakash, Saroj H, Bhat KM. LC determination and pharmacokinetics of meloxicam.. J Pharm Biomed Anal 2002 Jun 1;28(5):999-1004.
    pubmed: 12039643doi: 10.1016/s0731-7085(02)00064-xgoogle scholar: lookup
  25. Health Canada. Guidance for Industry — Preparation of Veterinary Abbreviated New Drug Submissions — Generic Drugs. [Last accessed May 20, 2015]. Available from: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/vet/legislation/guide-ld/vdd-guide-ands-padn-eng.pdf.

Citations

This article has been cited 6 times.
  1. Mercer MA, Davis JL, McKenzie HC. The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses. Animals (Basel) 2023 May 10;13(10).
    doi: 10.3390/ani13101597pubmed: 37238029google scholar: lookup
  2. Song Y, Day CM, Afinjuomo F, Tan JE, Page SW, Garg S. Advanced Strategies of Drug Delivery via Oral, Topical, and Parenteral Administration Routes: Where Do Equine Medications Stand?. Pharmaceutics 2023 Jan 4;15(1).
    doi: 10.3390/pharmaceutics15010186pubmed: 36678815google scholar: lookup
  3. Castilla-Casadiego DA, Miranda-Muñoz KA, Roberts JL, Crowell AD, Gonzalez-Nino D, Choudhury D, Aparicio-Solis FO, Servoss SL, Rosales AM, Prinz G, Zou M, Zhang Y, Coetzee JF, Greenlee LF, Powell J, Almodovar J. Biodegradable microneedle patch for delivery of meloxicam for managing pain in cattle. PLoS One 2022;17(8):e0272169.
    doi: 10.1371/journal.pone.0272169pubmed: 35917312google scholar: lookup
  4. Pearson JM, Pajor EA, Campbell JR, Caulkett NA, Levy M, Dorin C, Windeyer MC. Clinical impacts of administering a nonsteroidal anti-inflammatory drug to beef calves after assisted calving on pain and inflammation, passive immunity, health, and growth. J Anim Sci 2019 Apr 29;97(5):1996-2008.
    doi: 10.1093/jas/skz094pubmed: 30896739google scholar: lookup
  5. Mendoza FJ, Serrano-Rodriguez JM, Perez-Ecija A. Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses. J Vet Intern Med 2019 Mar;33(2):961-967.
    doi: 10.1111/jvim.15433pubmed: 30768821google scholar: lookup
  6. Banse H, Cribb AE. Comparative efficacy of oral meloxicam and phenylbutazone in 2 experimental pain models in the horse. Can Vet J 2017 Feb;58(2):157-167.
    pubmed: 28216685
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.